Please enable JS

Investors & Media

OVERVIEW

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead program, CTX001, aims to treat Sickle cell disease and ß-thalassemia using an ex vivo approach. We are also pursuing oncology indications with our allogeneic CAR-T platform and liver, lung, and neuromuscular indications using in vivo approaches. In addition, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and select business operations in London, United Kingdom.

 

For more information on the foundational CRISPR/Cas9 patent estate, please visit the CRISPR Collective website here.






Upcoming Events & Recent Presentations

DateTitle
5/15/18
 2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9
4/16/18
 2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen
4/16/18
 2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells
12/10/17
 2017 American Society of Hematology Annual Meeting Presentation: CRISPR/Cas9 Genome Editing to Treat Sickle Cell Disease and ß-Thalassemia: Re-Creating Genetic Variants to Upregulate Fetal Hemoglobin Appear Well-Tolerated, Effective and Durable
11/10/17
 SITC 2017 Investor Reception Presentation
11/10/17
 Production of Site-specific Allogeneic CAR-T Cells by CRISPR/Cas9 for B-Cell Malignancies
6/23/17
 2017 European Hematology Association Annual Congress Presentation
5/23/17
 UBS Global Healthcare Conference Presentation
5/03/17
 42nd Annual Deutsche Bank Health Care Conference Presentation
4/06/17
 2017 Needham Conference Presentation
12/06/16
 Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to treat Sickle Cell Disease and ß-thalassemia poster presented at the 2016 American Society of Hematology Annual Meeting
12/06/16
 CRISPR/Cas9-mediated genome editing of Human CD34+ cells upregulate fetal hemoglobin to clinically relevant levels in single cell-derived erythroid colonies poster presented at the 2016 American Society of Hematology Annual Meeting

View More




Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet